Â鶹ӰԺ

Eleven university innovators pitched their innovations at Lab Venture Challenge (LVC), an annual funding competition hosted by Venture Partners at CU Â鶹ӰԺ that accelerates commercially promising technologies accelerate into impactful business ventures.

Co-founded by CU Â鶹ӰԺ professor Mike McGehee, Tynt has raised $8.5 million in seed funding to scale its reversible metal electrodeposition (RME) technology, which is used to create blackout windows that aim to increase home comfort, privacy and energy efficiency.

Startup company founders who commercialize CU Â鶹ӰԺ’s research innovations will be getting a boost in 2022. Ascent, a startup accelerator specifically created for CU Â鶹ӰԺ innovators, will help founders launch their companies, raise investment capital, and gain market and partnership traction.

Aspero Medical received a U.S. patent for its planned medical device, a new balloon catheter for use in gastrointestinal endoscopies. The patent means Aspero can seek FDA approval this year and, if successful, commercialization in early 2022.

These highly competitive grant programs encourage research by small U.S. businesses with the aim of putting innovative products on the market. STTR also requires businesses to collaborate with nonprofit research institutions like CU Â鶹ӰԺ.

Meati, which uses the roots of mushrooms to produce whole cuts, was founded in 2019 by Tyler Huggins and CTO Justin Whiteley, who met at CU Â鶹ӰԺ while working toward their own PhDs. Whiteley specialized in materials, while Huggins was a former field biologist who discovered the power of mycelium.

BizWest examines how technology-transfer and accelerator entities at CU Â鶹ӰԺ and Colorado State University are helping boost new innovations that address COVID-19's widespread economic and social impact.

Solid Power, an industry-leading producer of all solid-state batteries for electric vehicles, announced a $130M Series B investment round, positioning them to produce full-scale batteries and expand in-house production for future vehicle integration.

As synthetic biology continues to grow, advanced benchtop systems are making research and product development easier. Now, Inscripta has announced the first commercial shipment of its groundbreaking, fully-automated Onyx platform.

OnKure develops best-in-class, targeted oncology therapeutics. New financing will be used to further clinical development of the company’s next-gen histone deacetylase (HDAC) inhibitors and fund a growing pipeline of earlier-stage molecules.